News Releases

Mirum Pharmaceuticals to Present New Data at The Liver Meeting 2019

FOSTER CITY, Calif. --(BUSINESS WIRE)--Oct. 1, 2019-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that multiple maralixibat

Mirum Pharmaceuticals to Present at Cantor 2019 Global Healthcare Conference

FOSTER CITY, Calif. --(BUSINESS WIRE)--Sep. 26, 2019-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that company management will

Mirum Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update

FOSTER CITY, Calif. --(BUSINESS WIRE)--Aug. 28, 2019-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today reported financial results for the

Mirum Pharmaceuticals Announces Pricing of Initial Public Offering

FOSTER CITY, Calif. , July 17, 2019 /PRNewswire/ -- Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company developing a novel approach for treating cholestatic liver diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price

Mirum Pharmaceuticals Initiates Phase 3 Clinical Trial for Pediatric Patients with Progressive Familial Intrahepatic Cholestasis

First patient dosed in Phase 3 trial evaluating efficacy and safety of maralixibat Topline results expected in fourth quarter of 2020 FOSTER CITY, Calif. , July 9, 2019 /PRNewswire/ -- Mirum Pharmaceuticals today announced the dosing of the first patient in the Phase 3 MARCH-PFIC clinical trial of

Mirum Pharmaceuticals Presents New Data Demonstrating Durable Improvements in Clinical Outcome Measures in Patients with PFIC2 and Alagille Syndrome Treated with Maralixibat

Late breaker presentation of long-term analysis of Phase 2 INDIGO study shows sustained response and clinically-relevant growth accelerations in PFIC2 responders Data from Phase 2b ICONIC study show profound and durable improvements in itch severity and serum bile acids in children with Alagille

Mirum Pharmaceuticals to Present Phase 2 Clinical Results of Maralixibat in Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis at the International Liver Congress

Maralixibat shows reductions in pruritus and serum bile acids in 48 week analysis of ICONIC Phase 2b study in Alagille syndrome patients Long-term analysis of INDIGO study of maralixibat shows sustained response and growth improvements in progressive familial intrahepatic cholestasis type two

Mirum Pharmaceuticals Appoints Chris Peetz as Chief Executive Officer

Mike Grey to Remain with Mirum in Role of Executive Chairman FOSTER CITY, Calif. , March 21, 2019 /PRNewswire/ -- Mirum Pharmaceuticals today announced the appointment of Chris Peetz as chief executive officer. The company's former CEO, Mike Grey , will stay on with Mirum in the role of executive

News Releases

News Releases

Header Menu